The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Interleukin 6 is essential for in vivo development of B lineage neoplasms.
Open accessAbstract
Interleukin (IL) 6 has been suggested to be the major cytokine responsible for proliferation of neoplastic plasma cells in both human myeloma and mouse plasmacytoma. Much of the evidence supporting this suggestion is derived from in vitro studies in which the survival or proliferation of some plasma cell tumors has been found to be IL-6 dependent. However, it remains unclear whether this dependency is the consequence of in vivo or in vitro selective pressures that preferentially expand IL-6-responsive tumor cells, or whether it reflects a critical in vivo role for IL-6 in plasma cell neoplasia. To address this question, we have attempted to induce plasma cell tumors in normal mice and in IL-6-deficient mice generated by introduction of a germline-encoded null mutation in the IL-6 gene. The results demonstrate that mice homozygous (+/+) or heterozygous (+/-) for the wild-type IL-6 allele yield the expected incidences of plasma cell tumors. In contrast, mice homozygous for the IL-6-null allele (-/-) are completely resistant to plasma cell tumor development. These studies define the essential role of IL-6 in the development of B lineage tumors in vivo and provide experimental support for continued efforts to modulate this cytokine in the treatment of appropriate human B cell malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768
Self-citationAutocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
The role of interleukin-6 in mucosal IgA antibody responses in vivo
Ramsay, A. J., Husband, A. J., Ramshaw, L. A., Bao, S., Matthaei, K. I., Koehler, G., & Kopf, M. (1994) · Science · doi:10.1126/science.8160012 · Cited by 454
Cited by
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282
Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,190
BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., Feng, P., Soppet, D., Charters, M., Gentz, R., Parmelee, D., et al. (1999) · Science · doi:10.1126/science.285.5425.260 · Cited by 1,144
Self-citationInflammation and cancer: An ancient link with novel potentials
Perwez Hussain, S., & Harris, C. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.23173 · Cited by 1,097
Sack, D. A., Sack, R. B., Nair, G. B., & Siddique, A. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15328-7 · Cited by 905
SOCS3 negatively regulates IL-6 signaling in vivo
Croker, B. A., Krebs, D. L., Zhang, J.-G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Förster, I., Clausen, B. E., et al. (2003) · Nature Immunology · doi:10.1038/ni931 · Cited by 840
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
Ishihara, K., & Hirano, T. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00027-8 · Cited by 807
Interleukin 6 and its receptor: ten years later
Hirano, T. (1998) · International Reviews of Immunology · doi:10.3109/08830189809042997 · Cited by 788
Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow
Halliley, J. L., Tipton, C. M., Liesveld, J., Rosenberg, A. F., Darce, J., Gregoretti, I. V., Popova, L., Kaminiski, D., Fucile, C. F., Albizua, I., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.016 · Cited by 545
Map kinase signaling pathways and hematologic malignancies
Platanias, L. C. (2003) · Blood · doi:10.1182/blood-2002-12-3647 · Cited by 432
Rothman, N., Skibola, C. F., Wang, S. S., Morgan, G., Lan, Q., Smith, M. T., Spinelli, J. J., Willett, E., De Sanjose, S., Cocco, P., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70434-4 · Cited by 381
Interleukin-6 in bone metastasis and cancer progression
Ara, T., & DeClerck, Y. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 379
Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8).
Schulz, T. F. (1998) · Journal of General Virology · doi:10.1099/0022-1317-79-7-1573 · Cited by 289
Paschoud, S., Dogar, A. M., Kuntz, C., Grisoni-Neupert, B., Richman, L., & Kühn, L. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01155-06 · Cited by 146
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
(1997) · Europe PMC (PubMed Central) · Cited by 111
Li, X., Zhou, Z.-Y., Zhang, Y.-Y., & Yang, H.-L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154677 · Cited by 89
Hilbert, D. M., Migone, T.-S., Kopf, M., Leonard, W. J., & Rudikoff, S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80312-x · Cited by 40
Self-citation
Metadata
- Authors
- Hilbert, D. M., Kopf, M., Mock, B. A., Köhler, G., & Rudikoff, S.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1995-07-01
- Volume
- 182
- Issue
- 1
- Pages
- 243-248
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2148662266
- Cited by
- 222
- References
- 3
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.